Tumorigenesis of papillary thyroid cancer is not BRAF-dependent in patients with acromegaly

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Kyung Kim, Hee ^a   Shin Lee, Ji ^a   Ho Park, Min ^a   Seong Cho, Jin ^a   Hee Yoon, Jee ^a   Jeong Kim, Soo ^a   Kang, Ho Cheol ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; GROWTH HORMONE; PARAFFIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; VALINE;

ACROMEGALY; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; ECHOGRAPHY; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PATIENT SELECTION; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SEX DIFFERENCE; THYROID NODULE; THYROID PAPILLARY CARCINOMA; TISSUE SECTION;

EID: 84908136023     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110241     Document Type: Article

References (40)

1. Loeper S, Ezzat S (2008) Acromegaly: Re-thinking the cancer risk. Rev Endocr Metab Disord 9: 41-58.
2. Jenkins PJ (2004) Acromegaly and cancer. Horm Res 62 Suppl 1: 108-115.
3. Gullu B, Celik O, Gazioglu N, Kadioglu P (2010) Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 13: 242-248.
4. Rogozinski A, Furioso A, Glikman P, Junco M, Laudi R, et al. (2012) Thyroid nodules in acromegaly. Arq Bras Endocrinol Metabol 56: 300-304.
5. Dagdelen S, Cinar N, Erbas T (2013) Increased thyroid cancer risk in acromegaly. Pituitary: July 09, Epub.
6. Wolinski K, Czarnywojtek A, Ruchala M (2014) Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly-meta-analysis and systematic review. PLoS One 9: e88787.
7. Siegel G, Tomer Y (2005) Is there an association between acromegaly and thyroid carcinoma? A critical review of the literature. Endocr Res 31: 51-58.
8. Xing M (2007) BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28: 742-762.
9. Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, et al. (2006) Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 65: 660-666.
10. Kim SK, Kim DL, Han HS, Kim WS, Kim SJ, et al. (2008) Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 17: 118-125.
11. Lim JY, Hong SW, Lee YS, Kim BW, Park CS, et al. (2013) Clinicopathologic implications of the BRAFV600E mutation in papillary thyroid cancer; a subgroup analysis of 3130 cases in a single center. Thyroid 23: 1423-1430.
12. Caronia LM, Phay JE, Shah MH (2011) Role of BRAF in thyroid oncogenesis. Clin Cancer Res 17: 7511-7517.
13. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, et al. (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85: 526-529.
14. Kim EK, Park CS, Chung WY, Oh KK, Kim DI, et al. (2002) New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol 178: 687-691.
15. Mountzios G, Kostopoulos I, Kotoula V, Sfakianaki I, Fountzilas E, et al. (2013) Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer. PLoS One 8: e54048.
16. Oh EY, Jang HW, Lee JI, Kim HK, Kim SW, et al. (2010) Prevalence of thyroid nodules and cancer detected by ultrasonograophy in healthy Korean adults: Clinical features and the risk for malignancy. J Korean Thyroid Assoc 3: 142-148.
17. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
18. Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, et al. (2013) Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat 45: 1-14.
19. Orme SM, McNally RJQ, Cartwright RA, Belchetz PE, Group ftUKAS (1998) Mortality and cancer incidence in acromegaly: A retrospective cohort study. J Clin Endocrinol Metab 83: 2730-2734.
20. Baris D, Gridley G, Ron E, Weiderpass E, Mellemkjaer L, et al. (2002) Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer Causes Control 13: 395-400.
21. Terzolo M, Tappero G, Borretta G, Asnaghi G, Pia A, et al. (1994) High prevalence of colonic polyps in patients with acromegaly. Influence of sex and age. Arch Intern Med 154: 1272-1276.
22. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, et al. (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87: 4054-4058.
23. Onoda N, Ohmura E, Tsushima T, Ohba Y, Emoto N, et al. (1992) Autocrine role of insulin-like growth factor (IGF)-I in a human thyroid cancer cell line. Eur J Cancer 28A: 1904-1909.
24. Yashiro T, Ohba Y, Murakami H, Obara T, Tsushima T, et al. (1989) Expression of insulin-like growth factor receptors in primary human thyroid neoplasms. Acta Endocrinol (Copenh) 121: 112-120.
25. dos Santos MC, Nascimento GC, Nascimento AG, Carvalho VC, Lopes MH, et al. (2013) Thyroid cancer in patients with acromegaly: a case-control study. Pituitary 16: 109-114.
26. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89: 667-674.
27. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT, Jr. (1995) Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16: 143-163.
28. Myers MG, Jr., Grammer TC, Wang LM, Sun XJ, Pierce JH, et al. (1994) Insulin receptor substrate-1 mediates phosphatidylinositol 3′-kinase and p70S6k signaling during insulin, insulin-like growth factor-1, and interleukin-4 stimulation. J Biol Chem 269: 28783-28789.
29. Saji M, Tsushima T, Isozaki O, Murakami H, Ohba Y, et al. (1987) Interaction of insulin-like growth factor I with porcine thyroid cells cultured in monolayer. Endocrinology 121: 749-756.
30. Tode B, Serio M, Rotella CM, Galli G, Franceschelli F, et al. (1989) Insulin-like growth factor-I: autocrine secretion by human thyroid follicular cells in primary culture. J Clin Endocrinol Metab 69: 639-647.
31. Ouban A, Muraca P, Yeatman T, Coppola D (2003) Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 34: 803-808.
32. Minuto F, Barreca A, Del Monte P, Cariola G, Torre GC, et al. (1989) Immunoreactive insulin-like growth factor I (IGF-I) and IGF-I-binding protein content in human thyroid tissue. J Clin Endocrinol Metab 68: 621-626.
33. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855-867.
34. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, et al. (2012) The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118: 1764-1773.
35. Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, et al. (2006) Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 169: 1875-1885.
36. Schoffski P, Adkins D, Blay JY, Gil T, Elias AD, et al. (2013) An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic softtissue sarcoma or Ewing family of tumours. Eur J Cancer 49: 3219-3228.
37. Harach HR, Franssila KO, Wasenius VM (1985) Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 56: 531-538.
38. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19: 1167-1214.
39. Gydee H, O'Neill JT, Patel A, Bauer AJ, Tuttle RM, et al. (2004) Differentiated thyroid carcinomas from children and adolescents express IGF-I and the IGF-I receptor (IGF-I-R). Cancers with the most intense IGF-I-R expression may be more aggressive. Pediatr Res 55: 709-715.
40. Maiorano E, Ciampolillo A, Viale G, Maisonneuve P, Ambrosi A, et al. (2000) Insulin-like growth factor 1 expression in thyroid tumors. Appl Immunohistochem Mol Morphol 8: 110-119.